Quince Therapeutics (QNCX) Investor Presentation summary

Investment highlights and market opportunity

• Lead asset eDSP in Phase 3 NEAT trial for Ataxia-Telangiectasia (A-T), a rare pediatric disease with no approved treatments and a $1+ billion commercial opportunity.

• NEAT trial enrollment completed with 105 participants; topline data expected Q1 2026.

• Strategic partnership with Option Care Health enables broad U.S. access and scalability for eDSP administration.

• $26.3 million in cash supports operations through topline results and into Q2 2026.

• Pipeline expansion targets Duchenne muscular dystrophy (DMD) and other rare immunology/autoimmune diseases.

eDSP technology and clinical profile

• eDSP encapsulates dexamethasone sodium phosphate in autologous red blood cells, enabling monthly dosing with reduced toxicity.

• Designed to deliver corticosteroid efficacy without adrenal suppression or other chronic steroid toxicities.

• Over 425 participants have received eDSP, including 240+ A-T patients and 7,800+ infusions.

• Demonstrated favorable safety profile versus conventional corticosteroids, with no hirsutism, delayed puberty, hyperglycemia, or excessive weight gain.

• 20+ years of R&D and $100 million invested in the AIDE technology platform.

Clinical efficacy and trial results

• Prior Phase 3 ATTEST study showed eDSP slowed neurological deterioration in A-T, especially in 6–9 year-olds, with significant improvements across multiple endpoints.

• No serious safety concerns observed in long-term use; well tolerated in both double-blind and open-label extension studies.

• NEAT trial design optimized based on ATTEST lessons, focusing on 6–9 year-olds as primary analysis population.

• High data integrity in NEAT with low missed dose and discontinuation rates, and 100% OLE rollover.

• RNA sequencing from ATTEST provides comprehensive molecular characterization and identifies potential biomarkers.